Author

J. Li

Institutions: Jiangsu Cancer Hospital, Nanjing Medical University

Observed institutions: Fujian Medical University, Central South University, Hunan Cancer Hospital, Jiangsu Cancer Hospital, Nanjing Medical University

OpenAlex ID: A5037998611

120P The predictive value of LATS1 mutation for immune checkpoint inhibitors therapy in bladder cancer

2022 · J. Li, Q. Zhang, et al. · Annals of Oncology · 3

2120P Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma

2025 · L. Lu, L. Xia, et al. · Annals of Oncology

2167P Comparative immune-pathological responses to neoadjuvant chemoimmunotherapy and chemotherapy in esophageal squamous cell carcinoma and development of a prognostic model

2025 · J. Li, W. Xiao Hua, et al. · Annals of Oncology

Efficacy of Immune Checkpoint Inhibitors in Advanced Esophageal Squamous Cell Carcinoma Patients with Hepatitis B

2024 · J. Pan, Q. Pan, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 5

Citation count: 3

H-index: 1

I10-index: